Tiger YKR, Jain S, Barta SK, et al. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma. Leukemia & lymphoma. 2024:1-10. doi:10.1080/10428194.2024.2329996Google ScholarDOIPubMed
Publications
Li H, Marin M, Farhat MR. Exploring gene content with pangenome gene graphs. ArXiv. 2024.Google ScholarPubMed
Honigberg MC, Economy KE, Pabón MA, et al. Coronary Microvascular Function Following Severe Preeclampsia. medRxiv : the preprint server for health sciences. 2024. doi:10.1101/2024.03.04.24303728Google ScholarDOIPubMed
Stenton SL, Pejaver V, Bergquist T, et al. Assessment of the evidence yield for the calibrated PP3/BP4 computational recommendations. medRxiv : the preprint server for health sciences. 2024. doi:10.1101/2024.03.05.24303807DOIGoogle ScholarPubMed
Fujita M, Gao Z, Zeng L, et al. Cell subtype-specific effects of genetic variation in the Alzheimer’s disease brain. Nature genetics. 2024. doi:10.1038/s41588-024-01685-yDOIGoogle ScholarPubMed
Huang HT, Lumpkin RJ, Tsai RW, et al. Ubiquitin-specific proximity labeling for the identification of E3 ligase substrates. Nature chemical biology. 2024. doi:10.1038/s41589-024-01590-9DOIGoogle ScholarPubMed
Funchain P, Ni Y, Heald B, et al. Germline Cancer Susceptibility in Individuals with Melanoma. Journal of the American Academy of Dermatology. 2024. doi:10.1016/j.jaad.2023.11.070DOIGoogle ScholarPubMed
Flechon L, Arib I, Dutta AK, et al. Genomic profiling of Mycosis Fungoides identifies patients at high risk of disease progression. Blood advances. 2024. doi:10.1182/bloodadvances.2023012125DOIGoogle ScholarPubMed
Calderon FA, Kang BH, Kyrysyuk O, et al. Targeting of the CD161 inhibitory receptor enhances T-cell-mediated immunity against hematological malignancies. Blood. 2024;143(12):1124-1138. doi:10.1182/blood.2023022882DOIGoogle ScholarPubMed